Please select the option that best describes you:
How do you approach management of a patient with mast cell leukemia?
Do you typically use avapritinib? If you do, what dose do you typically start at?
Answer from: at Academic Institution
Mast cell leukemia (MCL) is a rare and aggressive subtype of systemic mastocytosis defined by ≥20% mast cells in the bone marrow aspirate. A recent multicenter analysis of 92 patients with MCL had a median overall survival (OS) of 1.6 years. Midostaurin was the most common first-line therapy (45%...
Sign In or Register to read more